CORRECTING and REPLACING Smiths Detection Wins Biggest Ever Single Order for Next-Generation Hold Baggage Scanner for Frankfurt Airport
Please replace the release with the following corrected version due to multiple revisions to the headline, subhead and body of the release.
The corrected release reads:
SMITHS DETECTION WINS BIGGEST EVER SINGLE ORDER FOR NEXT-GENERATION HOLD BAGGAGE SCANNER FOR FRANKFURT AIRPORT
Advanced HI-SCAN 10080 XCT hold baggage scanners offer flexible, sophisticated detection capabilities
Smiths Detection has won its largest single order ever for its advanced HI-SCAN 10080 XCT hold baggage scanners, with an associated eight-year service agreement. The contract covers 35 of our HI-SCAN 10080 XCT next-generation scanners to support the upgrade to the ECAC Standard 3 explosives detection systems. The solution will deliver increased security and operational efficiency, and can easily be upgraded to meet future requirements to identify evolving threats, such as homemade explosives.
Frankfurt is Europe’s second busiest airport in terms of cargo and fourth in terms of passenger numbers, with over 60 million in 2016, making a high-speed, high volume hold baggage system critical to screening efficiency.
The HI-SCAN 10080 XCT scanner combines high-resolution X-ray technology, medical-quality computed tomography (CT) and advanced detection algorithms to deliver exceptional levels of security. It supports a high throughput of up to 1,800 bags per hour, can accommodate items measuring up to 1,000 x 800 mm, and operates with a low false alarm rate to deliver a highly efficient screening process.
Delivery will take place on a rolling basis between 2018 and 2021 with the order also including an eight year service agreement. The scanners will be used in Terminals 1 and 2 and will be operated by the German Federal Police.
“This contract represents our largest single order to date for ECAC Standard 3-compliant hold baggage scanners,” commented Tony Tielen, VP of EMEA for Smiths Detection. “Frankfurt was one of the very first airports we supplied with security equipment over fifty years ago, and we’re delighted to have the opportunity to continue protecting Germany’s busiest airport.”
Notes to editors
HI-SCAN 10080 XCT key features:
- EU/ECAC EDS Standard 3 approved
- Laboratory certified for high-speed checked baggage screening by the United States Transportation Security Administration (TSA)
- Belt speed of 0.5m/sec (98.5ft/min)
- High throughput of up to 1800 bags per hour
- Large tunnel capable of screening objects 100 x 80 cm (39.4 x 31.5in)
A dual-energy X-ray line scanner with full 3D volumetric Computed Tomography (CT) imaging and reconstruction, the HI-SCAN 10080 XCT is the next generation high-speed checked baggage explosives detection system (EDS).
With a belt speed of 0.5m/sec (98.5ft/min) and a large 1070 x 810mm (42.1 x 31.9in) rectangular tunnel, the HI-SCAN 10080 XCT provides the most economical solution for airport checked baggage screening requirements. This combination of belt speed and tunnel size will provide baggage handling systems the capability to process a throughput of up to 1800 bags/hour with object sizes of up to 1000 x 800 mm (39.4 x 31.5in).
The HI-SCAN 10080 XCT is designed to integrate easily into newly implemented Hold Baggage System (HBS) configurations or as a replacement for current baggage handling systems.
Further details on the Smiths Detection HI-SCAN 10080 XCT can be found here: http://www.smithsdetection.com/index.php?option=com_k2&view=item&id=157:hi-scan-10080-xct&Itemid=101&lang=en#.WKwoEoXXLmg
About Smiths Detection
Smiths Detection, part of Smiths Group, is a global leader in threat detection and screening technologies for military, air transportation, homeland security and emergency response markets. Our experience and history across more than 50 years at the frontline, enables us to provide unrivalled levels of expertise to detect and identify constantly changing chemical, radiological, nuclear and explosive threats, as well as weapons, dangerous goods, contraband and narcotics.
Our goal is simple – to provide security, peace of mind and freedom of movement upon which the world depends. For more information visit www.smithsdetection.com; or follow us on LinkedIn at www.linkedin.com/company/smiths-detection; YouTube at www.youtube.com/user/smithsdetectiongroup; or Twitter at twitter.com/smithsdetection.
Global Aviation Marketing Director
+49 (0)611 9412 422
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i